Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Complera Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Complera Prior Authorization for HIV-1 Treatment

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs prior authorization and coverage criteria for Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for adult patients with HIV-1 infection. It applies to providers requesting coverage through Ventura County Health Care Plan.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyComplera Prior Authorization for HIV-1 Treatment
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJan 28, 2014
    Last ReviewFeb 18, 2025
    Next Review DateN/A
    Key ActionComplera must be prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine certification or by a physician board-certified in Infectious Disease.
    SourceLink
    POLICY UPDATE CHANGES

    The 2/18/25 revision history identifies content revisions to the dosing, adverse reaction, and U.S. boxed warning sections.

    1 tablet dailyAdult HIV dosing
    ≤100,000Treatment-naive HIV-1 RNA limit
    <50Suppressed HIV-1 RNA threshold
    ≥6 monthsStable regimen duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≤200
    Do-not-use CD4 threshold

    General Coverage Requirements

    Initial or Replacement Therapy

    Covered for use as a complete regimen when the patient meets ANY of the following pathways:

    ONE of the following

    • Initial therapy

      • Adult patient is antiretroviral treatment-naive.
      • Patient has HIV-1 infection.
      • Therapy is used as a complete regimen.
      • HIV-1 RNA is at or below 100,000 copies/mL at the start of therapy.≤ 100,000 copies/mL
    • Replacement therapy

      • Adult patient is virologically suppressed, with HIV-1 RNA below 50 copies/mL.< 50 copies/mL
      • Patient has been on a stable antiretroviral regimen for at least 6 months.≥ 6 months
      • There has been no treatment failure.
      • There have been no substitutions due to resistance to emtricitabine, rilpivirine, or tenofovir disoproxil fumarate.
      • Therapy is used to replace the current antiretroviral treatment regimen.

    Do not use in patients with HIV RNA ≥100,000 copies/mL and/or CD4 count ≤200 cells/mm³.

    Contraindicated in patients with renal impairment with creatinine clearance (ClCr) <50 mL/minute or end-stage renal disease (ESRD) requiring dialysis.

    Contraindicated with concurrent use of carbamazepine, dexamethasone (>1 dose), oxcarbazepine, phenobarbital, phenytoin, proton pump inhibitors (PPIs), rifabutin, rifampin, rifapentine, or St. John's wort.

    Treatment-Naive Adult Initial Therapy

    Treatment-Naive Adult Initial Therapy

    Covered as a complete regimen for treatment-naive adults when all criteria are met.

    Initial therapy: The patient is an antiretroviral treatment-naive adult with HIV-1 RNA ≤100,000 copies/mL at the start of therapy.HIV-1 RNA ≤100,000 copies/mL

    Complera must be used as a complete regimen.

    Replacement Therapy

    Replacement Therapy

    Covered for replacement of a current antiretroviral regimen when all criteria are met.

    Virologically suppressed replacement therapy: The adult patient has HIV-1 RNA <50 copies/mL, has been on a stable antiretroviral regimen for ≥6 months, has had no treatment failure, and has had no substitutions due to resistance to emtricitabine, rilpivirine, or tenofovir disoproxil fumarate.HIV-1 RNA <50 copies/mL; stable regimen ≥6 months

    Complera replaces the current antiretroviral regimen.

    Clinical Thresholds and Eligibility Values

    Treatment-naive baseline HIV-1 RNA
    Maximum baseline HIV-1 RNA≤100,000 copies/mL
    Applies toAntiretroviral treatment-naive adults
    TimingAt the start of therapy
    Virologically suppressed HIV-1 RNA
    Eligibility thresholdHIV-1 RNA <50 copies/mL
    Applies toVirologically suppressed adults switching antiretroviral therapy
    Additional requirementPatient must be on a stable antiretroviral regimen for ≥6 months

    Authorization and Denial Risks

    Prior Authorization

    Use a qualified HIV prescriber

    Complera must be prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification or by a physician boarded in Infectious Disease.

    Denial Risk

    Verify viral load and CD4 thresholds

    Use is not authorized when HIV RNA is ≥100,000 copies/mL or the CD4 count is ≤200 cells/mm³. Verify that the patient meets the applicable HIV-1 RNA criteria before requesting coverage.

    • Treatment-naive adults: HIV-1 RNA ≤100,000 copies/mL at treatment initiation.
    • Do not use when HIV RNA is ≥100,000 copies/mL and/or CD4 count is ≤200 cells/mm³.

    Product and Clinical Background

    Complera combines emtricitabine, rilpivirine, and tenofovir disoproxil fumarate in a complete antiretroviral regimen. These agents inhibit HIV reverse transcriptase and suppress HIV viral replication. The policy applies to selected adults who are antiretroviral treatment-naive or who are virologically suppressed and switching from a stable antiretroviral regimen. Patients coinfected with hepatitis B require monitoring because discontinuation or treatment changes may cause severe acute hepatitis B exacerbations.

    Eligibility Definitions

    Antiretroviral treatment-naive
    DefinitionA patient who has not previously received antiretroviral treatment
    Eligible populationAdult patients with HIV-1 infection
    Use contextComplera may be used as a complete regimen for initial therapy
    Virologically suppressed
    HIV-1 RNABelow 50 copies/mL
    Stable regimenAntiretroviral regimen maintained for at least 6 months
    DefinitionAn adult with HIV-1 RNA below 50 copies/mL who has remained on a stable antiretroviral regimen for at least 6 months

    Dosage and Quantity Limit

    Complera
    DoseOne tablet
    FrequencyOnce daily
    AdministrationOral administration with food
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyComplera Prior Authorization for HIV-1 Treatment
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJan 28, 2014
    Last ReviewFeb 18, 2025
    Next Review DateN/A
    Key ActionComplera must be prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine certification or by a physician board-certified in Infectious Disease.
    SourceLink
    On This Page
    General Coverage RequirementsTreatment-Naive Adult Initial TherapyReplacement TherapyClinical Thresholds and Eligibility ValuesAuthorization and Denial RisksProduct and Clinical BackgroundEligibility DefinitionsDosage and Quantity Limit
    Stable antiretroviral regimen
    Minimum duration≥6 months
    RegimenStable antiretroviral regimen
    PurposeReplacement of the current antiretroviral treatment regimen
    CD4 count
    Do-not-use thresholdCD4 count ≤200 cells/mm³
    RestrictionDo not use in patients at or below this CD4 count
    Related HIV RNA restrictionDo not use when HIV RNA is ≥100,000 copies/mL
    Creatinine clearance
    Renal contraindicationCreatinine clearance <50 mL/minute
    Additional contraindicationEnd-stage renal disease requiring dialysis
    Clinical implicationDo not use with the stated renal impairment or dialysis requirement
    Denial Risk

    Screen for renal contraindications

    Coverage is precluded by renal impairment with creatinine clearance below 50 mL/minute or end-stage renal disease requiring dialysis.

    • Creatinine clearance must be at least 50 mL/minute.
    • Do not use in end-stage renal disease requiring dialysis.
    Denial Risk

    Review interacting medications

    Coverage is precluded with concurrent use of carbamazepine, dexamethasone greater than one dose, oxcarbazepine, phenobarbital, phenytoin, proton pump inhibitors, rifabutin, rifampin, rifapentine, or St. John’s wort.

    • Review the complete medication list for these contraindicated concomitant medications before requesting coverage.
    Denial Risk

    Confirm no treatment failure or resistance

    For replacement therapy, authorization requires no prior treatment failure and no substitutions caused by resistance to emtricitabine, rilpivirine, or tenofovir disoproxil fumarate.

    • Replacement candidates must have HIV-1 RNA <50 copies/mL.
    • The patient must have been on a stable antiretroviral regimen for ≥6 months.